A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia
<strong>Background</strong> The dengue vaccination era began when Dengvaxia (CYD-TDV) became available in 2016. In addition, several second-generation vaccine candidates are currently in phase 3 trials, suggesting that a broader availability of dengue vaccines may be possible in the near...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2018
|
| _version_ | 1797075846445400064 |
|---|---|
| author | Lee, J Lourenço, J Gupta, S Farlow, A |
| author_facet | Lee, J Lourenço, J Gupta, S Farlow, A |
| author_sort | Lee, J |
| collection | OXFORD |
| description | <strong>Background</strong> The dengue vaccination era began when Dengvaxia (CYD-TDV) became available in 2016. In addition, several second-generation vaccine candidates are currently in phase 3 trials, suggesting that a broader availability of dengue vaccines may be possible in the near future. Advancing on the recent WHO-SAGE recommendations for the safe and effective use of CYD-TDV at the regional level on average, this study investigates the vaccination impacts and cost-effectiveness of CYD-TDV and of a hypothetical new vaccine candidate (NVC) in a country-specific manner for three endemic countries: Vietnam, Thailand, and Colombia. <strong>Methods</strong> The vaccination impacts of CYD-TDV and NVC were derived by fitting the empirical seroprevalence rates of 9 year olds into an individual-based meta-population transmission model, previously used for the WHO-SAGE working group. The disability-adjusted life years were estimated by applying country-specific parametric values. The cost-effectiveness analyses of four intervention strategies in combination with routine and catch-up campaigns were compared for both vaccines to inform decision makers regarding the most suitable immunization program in each of the three countries. <strong>Results and conclusion</strong> Both CYD-TDV and NVC could be cost-effective at the DALY threshold cost of $2000 depending upon vaccination costs. With CYD-TDV, targeting 9 year olds in routine vaccination programs and 10–29 year olds as a one-off catch-up campaign was the most cost-effective strategy in all three countries. With NVC, while the most cost-effective strategy was to vaccinate 9–29 and 9–18 year olds in Vietnam and Thailand respectively, vaccinating younger age cohorts between 1 and 5 years old in Colombia was more cost-effective than other strategies. Given that three countries will soon face decisions regarding whether and how to incorporate CYD-TDV or future dengue vaccines into their budget-constrained national immunization programs, the current study outcomes can be used to help decision makers understand the expected impacts and cost-effectiveness of such vaccines. |
| first_indexed | 2024-03-06T23:55:58Z |
| format | Journal article |
| id | oxford-uuid:7438fbcb-2b84-467a-9c6f-71d38527be78 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T23:55:58Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7438fbcb-2b84-467a-9c6f-71d38527be782022-03-26T20:01:21ZA multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and ColombiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7438fbcb-2b84-467a-9c6f-71d38527be78Symplectic Elements at OxfordElsevier2018Lee, JLourenço, JGupta, SFarlow, A<strong>Background</strong> The dengue vaccination era began when Dengvaxia (CYD-TDV) became available in 2016. In addition, several second-generation vaccine candidates are currently in phase 3 trials, suggesting that a broader availability of dengue vaccines may be possible in the near future. Advancing on the recent WHO-SAGE recommendations for the safe and effective use of CYD-TDV at the regional level on average, this study investigates the vaccination impacts and cost-effectiveness of CYD-TDV and of a hypothetical new vaccine candidate (NVC) in a country-specific manner for three endemic countries: Vietnam, Thailand, and Colombia. <strong>Methods</strong> The vaccination impacts of CYD-TDV and NVC were derived by fitting the empirical seroprevalence rates of 9 year olds into an individual-based meta-population transmission model, previously used for the WHO-SAGE working group. The disability-adjusted life years were estimated by applying country-specific parametric values. The cost-effectiveness analyses of four intervention strategies in combination with routine and catch-up campaigns were compared for both vaccines to inform decision makers regarding the most suitable immunization program in each of the three countries. <strong>Results and conclusion</strong> Both CYD-TDV and NVC could be cost-effective at the DALY threshold cost of $2000 depending upon vaccination costs. With CYD-TDV, targeting 9 year olds in routine vaccination programs and 10–29 year olds as a one-off catch-up campaign was the most cost-effective strategy in all three countries. With NVC, while the most cost-effective strategy was to vaccinate 9–29 and 9–18 year olds in Vietnam and Thailand respectively, vaccinating younger age cohorts between 1 and 5 years old in Colombia was more cost-effective than other strategies. Given that three countries will soon face decisions regarding whether and how to incorporate CYD-TDV or future dengue vaccines into their budget-constrained national immunization programs, the current study outcomes can be used to help decision makers understand the expected impacts and cost-effectiveness of such vaccines. |
| spellingShingle | Lee, J Lourenço, J Gupta, S Farlow, A A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia |
| title | A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia |
| title_full | A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia |
| title_fullStr | A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia |
| title_full_unstemmed | A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia |
| title_short | A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia |
| title_sort | multi country study of dengue vaccination strategies with dengvaxia and a future vaccine candidate in three dengue endemic countries vietnam thailand and colombia |
| work_keys_str_mv | AT leej amulticountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT lourencoj amulticountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT guptas amulticountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT farlowa amulticountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT leej multicountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT lourencoj multicountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT guptas multicountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia AT farlowa multicountrystudyofdenguevaccinationstrategieswithdengvaxiaandafuturevaccinecandidateinthreedengueendemiccountriesvietnamthailandandcolombia |